CELL PhenomeX Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CELL

Price (delayed)

$0.7126

Market cap

$70.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.42

Enterprise value

$42.82M

Berkeley Lights, Inc. operates as a biotechnology company. The Company provides technology solutions for single cell manipulation for biopharma, diagnostics, and life science research. Berkeley Lights serves customers worldwide.

Highlights
The gross margin has increased by 4.2% YoY
The company's equity fell by 18% YoY but it rose by 11% QoQ
PhenomeX's debt has surged by 121% QoQ and by 117% YoY
The quick ratio has shrunk by 53% YoY and by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.berkeleylights.com

Key stats

What are the main financial stats of CELL
Market
Shares outstanding
98.8M
Market cap
$70.4M
Enterprise value
$42.82M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.33
Price to sales (P/S)
0.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.56
Earnings
Revenue
$76.91M
EBIT
-$98.86M
EBITDA
-$86.47M
Free cash flow
-$61.14M
Per share
EPS
-$1.42
Free cash flow per share
-$0.81
Book value per share
$2.19
Revenue per share
$1.02
TBVPS
$3.5
Balance sheet
Total assets
$300.56M
Total liabilities
$142.82M
Debt
$94.12M
Equity
$157.74M
Working capital
$84.2M
Liquidity
Debt to equity
0.6
Current ratio
2.77
Quick ratio
3.09
Net debt/EBITDA
0.32
Margins
EBITDA margin
-112.4%
Gross margin
69.4%
Net margin
-130.1%
Operating margin
-129.5%
Efficiency
Return on assets
-39.6%
Return on equity
-63.3%
Return on invested capital
-69.3%
Return on capital employed
-39.1%
Return on sales
-128.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CELL stock price

How has the PhenomeX stock price performed over time
Intraday
1.15%
1 week
-16.27%
1 month
-37.49%
1 year
-84.51%
YTD
-73.41%
QTD
-38.57%

Financial performance

How have PhenomeX's revenue and profit performed over time
Revenue
$76.91M
Gross profit
$53.38M
Operating income
-$99.61M
Net income
-$100.03M
Gross margin
69.4%
Net margin
-130.1%
PhenomeX's net margin has decreased by 46% YoY and by 4.3% QoQ
The operating margin has declined by 46% year-on-year and by 3.8% since the previous quarter
The company's operating income fell by 30% YoY
The company's net income fell by 29% YoY and by 2% QoQ

Growth

What is PhenomeX's growth rate over time

Valuation

What is PhenomeX stock price valuation
P/E
N/A
P/B
0.33
P/S
0.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.56
PhenomeX's EPS has decreased by 22% YoY
CELL's price to book (P/B) is 73% lower than its last 4 quarters average of 1.2
The company's equity fell by 18% YoY but it rose by 11% QoQ
The price to sales (P/S) is 71% lower than the last 4 quarters average of 2.4
The company's revenue fell by 12% YoY and by 2.2% QoQ

Efficiency

How efficient is PhenomeX business performance
PhenomeX's return on equity has shrunk by 74% YoY and by 8% QoQ
PhenomeX's return on assets has decreased by 47% YoY
PhenomeX's return on sales has decreased by 46% YoY and by 4.1% QoQ
CELL's return on invested capital is up by 11% since the previous quarter

Dividends

What is CELL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CELL.

Financial health

How did PhenomeX financials performed over time
CELL's total assets is 110% greater than its total liabilities
The total liabilities has surged by 97% year-on-year and by 70% since the previous quarter
PhenomeX's current ratio has plunged by 63% YoY and by 29% from the previous quarter
PhenomeX's debt is 40% lower than its equity
CELL's debt to equity has surged by 173% year-on-year and by 100% since the previous quarter
PhenomeX's debt has surged by 121% QoQ and by 117% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.